These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 385712)

  • 1. Maximum allowable cost: can the government control drug costs?
    Smith MI; Wertheimer AI
    J Health Polit Policy Law; 1979; 4(2):155-75. PubMed ID: 385712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy.
    Paul SH
    Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270
    [No Abstract]   [Full Text] [Related]  

  • 3. Health Care Financing Administration: Pharmaceutical Reimbursement Board; final maximum allowable cost determinations.
    Fed Regist; 1979 Aug; 44(169):50651-6. PubMed ID: 10297564
    [No Abstract]   [Full Text] [Related]  

  • 4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New rules for US drug reimbursement.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the maximum allowable cost program.
    Lee AJ; Hefner D; Dobson A; Hardy R
    Health Care Financ Rev; 1983 Mar; 4(3):71-82. PubMed ID: 10309857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. States on the Front Line: Addressing America's Drug Pricing Problem.
    Riley T; Lanford S
    J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of drug regimen costs between the Medicare prescription discount program and other purchasing systems.
    Hayes JM; Walczak H; Prochazka A
    JAMA; 2005 Jul; 294(4):427-8. PubMed ID: 16046648
    [No Abstract]   [Full Text] [Related]  

  • 11. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
    Gudiksen KL; King JS
    J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
    [No Abstract]   [Full Text] [Related]  

  • 12. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gift giving.
    Raszkowski RR
    S D J Med; 2002 Dec; 55(12):513-4. PubMed ID: 12516357
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug product selection: the Florida experience.
    Vuturo GJ; Krischer JP; McCormick WC
    Am J Public Health; 1980 May; 70(5):479-84. PubMed ID: 7377418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimbursement of drug cost-medical assistance program.
    Hosp Formul; 1975 Mar; 10(3):120, 122, 142. PubMed ID: 10297178
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicare prescription drug plan costs and affordability--2007.
    Davis MM
    J Gen Intern Med; 2007 Aug; 22(8):1221-2. PubMed ID: 17497191
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescription drug pricing: the consumer perspective.
    Searing A
    N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
    Greene JA; Padula WV
    N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical reimbursement: an overview.
    Johnson PE
    Am J Health Syst Pharm; 2008 Jan; 65(2 Suppl 1):S4-10. PubMed ID: 18192246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.